Tixteller

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tixteller

Overview of Tixteller

Tixteller is a pharmaceutical formulation containing the active substance rifaximin. It belongs to a class of medications known as antibiotics. Unlike many other antibiotics that are absorbed into the bloodstream to treat infections throughout the body, Tixteller is non-systemic. This means it passes through the stomach and into the intestine without being significantly absorbed into the blood circulation.

Because it remains primarily within the gastrointestinal tract, its therapeutic effects are concentrated locally on the bacteria present in the gut.

Mechanism of Action

Tixteller works by inhibiting bacterial protein synthesis. It binds to the enzyme responsible for creating bacterial RNA, which prevents the bacteria from reproducing and maintaining their vital functions. By reducing the population of certain bacteria in the digestive system, the medication helps manage conditions where bacterial overgrowth or specific bacterial activity contributes to symptoms.

Primary Uses

Tixteller is used in adult patients for the management of specific gastrointestinal and hepatic conditions:

  • Hepatic Encephalopathy: In patients with advanced liver disease, the liver may struggle to remove toxins like ammonia from the blood. Bacteria in the digestive tract are a primary source of this ammonia. Tixteller is used to reduce these ammonia-producing bacteria, thereby lowering the risk of overt hepatic encephalopathy recurrence, a condition that affects brain function.
  • Irritable Bowel Syndrome with Diarrhea (IBS-D): It is also used to treat adults living with irritable bowel syndrome characterized by diarrhea. In this context, the medication helps regulate the gut flora to alleviate abdominal pain and improve stool consistency.

Physical Characteristics

Tixteller is typically produced as film-coated tablets for oral administration. The tablets are designed to ensure the active ingredient reaches the intended site of action within the intestinal tract.

Regulatory References

  1. Rifaximin: MedlinePlus Drug Information

What side effects are possible with Tixteller?

Possible Side Effects and Safety Information

The safety profile of Tixteller (Rifaximin) is formally documented by regulatory authorities, classifying possible adverse reactions by the frequency observed in clinical studies and by the physiological systems affected. As a non-systemic antibiotic, the safety profile reflects both local effects within the gastrointestinal tract and documented systemic reactions.


Adverse Reaction Classifications

Adverse reactions are grouped into categories based on occurrence rates, with common effects observed in clinical trials including headache, dizziness, abdominal pain, flatulence, and nausea.

Reactions are classified according to System-Organ Classes (SOCs), which include Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders. The official documentation also lists effects with a frequency Not known, such as certain severe cutaneous reactions.


Serious Safety Considerations

The regulatory profile recognizes the potential for serious adverse reactions. These include Clostridium difficile-Associated Diarrhea (CDAD), which is associated with nearly all antibacterial agents, and severe hypersensitivity reactions such as angioedema. Rare but severe cutaneous events like Stevens-Johnson syndrome (SJS) have also been documented.


Safety Constraints and Special Populations

Tixteller is contraindicated in patients with a known hypersensitivity to the drug or any rifamycin derivatives, and in individuals with a gastrointestinal obstruction. A key safety note concerns patients with severe hepatic impairment (Child-Pugh Class C); due to reduced metabolism in this population, systemic exposure to Rifaximin is substantially increased, warranting careful use as specified in official labeling. Additionally, preclinical data documented teratogenic effects in animals, which contributes to the official safety profile concerning use during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help — official regulatory information for Tixteller

The official regulatory documentation defines the Tixteller overdose profile primarily by establishing the required emergency response, as the drug's clinical presentation following acute overdosage is non-specific.

Documented Overdose Presentations: Based on controlled clinical trials, the adverse reactions observed in subjects who received doses higher than the maximum recommended dose were reported as similar to the reactions experienced by those receiving placebo. Regulatory labeling does not define a unique set of severe manifestations or specific clinical signs that are distinct from general known adverse reactions following acute overdosage. This profile implies that severe, unexpected toxicological outcomes are not formally documented.

Required Emergency Actions and Support: In the event of a known or suspected overdosage, regulatory bodies mandate that the product be discontinued. It is essential to contact a health professional, a hospital emergency department, or a regional Poison Control Centre immediately, even if no symptoms are currently apparent. Urgent medical attention may be needed to assess the situation. The required management approach involves initiating symptomatic treatment and instituting appropriate supportive measures based on the patient's clinical status.

Antidote and Specific Constraints: The official prescribing information for Tixteller includes the constraint that no specific information is available concerning the efficacy of a specific antidote for its overdosage. Furthermore, specific guidance on modifying overdose management or monitoring for patient subsets, such as those with hepatic impairment, is not explicitly detailed in the regulatory overdose sections.

Therapeutic Uses of Tixteller

What Tixteller Treats: Main Uses and Benefits

Tixteller is applied across domains where additional symptomatic support is needed in situations where patient discomfort or functional strain is heightened. The medication is considered relevant for managing specific conditions characterized by periods of heightened symptoms.


Easing Symptoms That Interfere with Daily Comfort

Tixteller is applied in addressing symptom clusters that may become intense or disruptive, and it is relevant for managing symptoms that interfere with daily comfort. This support assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations. It is commonly used across conditions presenting with acute episodes, including those associated with episodic symptoms like certain forms of irritable bowel distress and the specific liver complication known as hepatic encephalopathy.


Supportive Management for Symptom Fluctuations

This medicine is generally used across conditions presenting with episodic or fluctuating manifestations. It may assist with short-term symptom stabilization, contributing to easing the overall symptom load when symptoms become more noticeable. The medication is relevant in clinical settings marked by increased discomfort or tension, supporting general well-being during symptomatic phases.


Quick Fact: Supportive Management for Symptom Fluctuations

Tixteller is often used in situations involving certain distressing symptoms and tension, particularly when symptoms intensify and supportive relief is needed. The aim is to support patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tixteller?

This section outlines the official population eligibility and non-eligibility rules for Tixteller (Rifaximin) as defined in government regulatory documents.


Contraindicated Populations (Must Not Use)

Tixteller is strictly contraindicated if a patient has a known hypersensitivity to Rifaximin, any other rifamycin class antibiotic (e.g., rifampicin), or any inactive component of the tablet. Furthermore, the medicine must not be used for treating diarrhea that is complicated by the presence of fever or blood in the stool, as regulatory labeling specifies a limitation against use for diarrhea caused by invasive pathogens.


Age and Health Status Restrictions

Category Regulatory Eligibility Status
Hepatic Encephalopathy & IBS-D Not established in patients under 18 years of age
Traveler's Diarrhea Established only in patients 12 years and older
Severe Hepatic Impairment Restricted population; use requires caution due to increased systemic exposure (Child-Pugh Class C)
Pregnancy Not recommended as a precautionary measure
Lactation Decision to discontinue drug or breastfeeding must be made

Official documentation notes that safety and efficacy are not established in the specified pediatric groups. For patients with severe liver function compromise, the regulatory labeling mandates caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the interaction patterns for Tixteller (Rifaximin) as officially documented in government regulatory sources. As a non-systemic antibiotic, most interactions relate to drug transport and potential effects on systemically absorbed medicines.


Pharmacokinetic and Transporter Interactions

Tixteller is a substrate for the drug efflux transporter P-glycoprotein (P-gp). Co-administration with potent P-gp inhibitors, such as Cyclosporine, significantly increases the systemic exposure (Cmax and AUC) of Rifaximin.

Interacting Substance/Class Official Interaction Outcome
P-gp Inhibitors (e.g., Cyclosporine) Significant increase in Rifaximin systemic exposure.
Warfarin (Oral Anticoagulant) Reports of both decreases and increases in International Normalized Ratio (INR).
High-Fat Meal Observed to double Rifaximin systemic exposure (AUC).

Interaction-Related Constraints and Monitoring

Official regulatory documents require careful INR monitoring when Rifaximin is introduced or withdrawn for patients maintained on Warfarin. Although Rifaximin can be taken with or without food, a high-fat meal has been documented to alter exposure.

Caution is advised when co-administering with P-gp inhibitors, a concern that is heightened in patients with hepatic impairment due to their already increased Rifaximin exposure. In this patient population, it also cannot be excluded that Rifaximin may decrease the exposure of co-administered CYP3A4 substrates. Co-administration with other rifamycin antibacterial agents is generally not recommended.

Mechanism of Action

Targeted Inhibition of Bacterial RNA Synthesis

The primary mechanism involves the molecule's physical, non-covalent binding to the beta (beta) subunit of bacterial DNA-dependent RNA polymerase (RNA Pol). This interaction effectively blocks the enzyme's active site, arresting the initiation of RNA chain synthesis and thus preventing the bacterial cell from transcribing essential genetic information needed for protein production and replication. This molecular action targets proliferating, susceptible bacteria within the gut lumen; the drug's high localization limits systemic distribution.


Modulation of Gut Metabolite Burden and Physiological Impact

By reducing the population of certain susceptible bacteria in the intestine, the drug's mechanism leads to a substantial decrease in the local generation of bacterial-derived metabolites, such as ammonia. This biological cascade limits the absorption of these metabolites across the intestinal barrier into the portal circulation. The resulting physiological effect is a lowered absorption of bacterial metabolites, which influences the systemic metabolic load and contributes to the drug's overall effect profile.


Local Immune and Epithelial Pathway Modulation

Beyond its direct antibacterial effect, the mechanism of Rifaximin also involves modulation of the host's intestinal cells. Evidence suggests the drug can interfere with inflammatory signaling pathways, such as the NF-kappaB pathway, within the gut mucosa, contributing to a modulation of local inflammatory responses. This host-pathway modulation operates alongside the drug's primary local action, independent of systemic absorption.

Dosage and Administration Information

How to Use Tixteller

Tixteller (Rifaximin) is used according to fixed, context-dependent regimens, rather than being adjusted by patient weight. The medicine is consistently administered via the oral route as a film-coated tablet, ensuring the active agent is delivered directly to the gut lumen.


Official Administration Guidelines

The usage protocol is determined by the clinical context, which sets the specific dose, frequency, and duration.

Instruction Detail
Route of Administration Oral administration only.
Dosing Regimen & Frequency Varies by use pattern: 550 mg twice daily (BID) for long-term maintenance, or 550 mg three times daily (TID) for the 14-day course, or 200 mg three times daily (TID) for the 3-day course.
Timing in Relation to Meals May be taken with or without food, establishing flexibility in administration timing.
Duration and Retreatment Used for a 3-day course (short-term), a 14-day course (which may be repeated up to two additional times for recurrence), or on a long-term basis for maintenance.

Population and Procedural Context

Administration rules also define high-level population limits. The 200 mg regimen is approved for use in patients 12 years of age and older, while the 550 mg regimens are established for adults. For older adults, no specific dosage adjustment is necessary. When a dose is missed, patients should continue with the next scheduled dose and should not take a double dose to compensate. These rules establish a standardized procedural approach, defining the proper use of the medicine across its approved applications.

Recent Clinical Evidence

Research evidence / Overview of studies for Tixteller


1. Evidence for Use in Managing Recurrence of Hepatic Encephalopathy

Research explored the study of Tixteller in HE recurrence using large randomized controlled trials (RCTs). These studies included adults with cirrhosis and a prior history of overt HE. Research examined outcomes reflecting daily functioning and hospitalizations. Findings reported measurements of the time frame before the next acute episode occurred. However, follow-up durations were limited, and few data are available for patients with the most advanced liver impairment.


2. Evidence for Use in Irritable Bowel Distress (IBS-D)

Tixteller was evaluated in research examining IBS with Diarrhea (IBS-D) using placebo-controlled trials. Studies examined patient-reported outcomes describing perceived discomfort, tracking composite endpoints related to abdominal pain and stool consistency. Research reported patterns where measured outcomes addressed global IBS symptoms, but the measured change was not sustained indefinitely in all cases. Evidence is limited regarding the optimal approach for re-treatment courses, and the long-term course of this condition remains uncertain.


3. Evidence for Use in Acute Traveler's Diarrhea

Studies examined the use of Tixteller in acute, non-invasive Traveler’s Diarrhea via short-term RCTs. Researchers studied outcomes describing episodic changes, such as clinical cure and the Time to Last Unformed Stool (TLUS). Findings reported measurements of the time until the resolution of loose stools in the studied population. Data for certain groups remain insufficient, as the trials excluded patients with fever or blood in the stool, and research does not describe the use of this medicine for prophylaxis.


4. Long-Term Studies and Follow-up Data

Research was studied for how symptoms change over time across all indicated conditions. While some clinical trials included extension phases, the long-term effects are not fully established for every patient. Follow-up durations were limited in the primary trials, meaning data are still emerging to fully characterize outcomes over multiple years.


5. Evidence in Specific Patient Populations

The primary clinical research generally was evaluated in broad adult populations. The results apply only to the populations studied. Few data are available to fully describe outcomes for patients with the most severe underlying liver function impairment. Comparative evidence is lacking for many other specific patient groups.


6. Research Gaps and Areas of Uncertainty

The overall body of evidence highlights what is known — and what is still uncertain. Evidence quality varies across studies, and subgroup findings are uncertain in some areas. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Tixteller (FAQ)


Q: How quickly can I expect Tixteller to start working?

A: Studies and official information indicate that the time to observe symptomatic improvement can vary based on the condition being addressed. For example, in clinical studies examining acute Traveler’s Diarrhea, the median time until the resolution of loose stools was reported to be approximately 32.5 hours.


Q: Does Tixteller need to be taken long-term for the intended effect?

A: The duration of use for Tixteller is defined by the specific condition it is approved to address. Official regimens can range from a short, 3-day course for acute conditions to a long-term daily maintenance plan for chronic conditions like Hepatic Encephalopathy.


Q: Is there a known interaction between Tixteller and alcohol?

A: Official labeling does not document a specific, direct chemical interaction between Tixteller (Rifaximin) and alcohol. However, since the medicine may cause dizziness in some patients, concurrent consumption is noted in some patient information, and could contribute to the occurrence of this side effect.


Q: Are there any food restrictions while taking Tixteller?

A: According to the official product information, Tixteller may be taken with or without food, establishing flexibility in administration. Although a high-fat meal may lead to a slight increase in the amount of drug absorbed into the body, this change is not described as a key constraint that would require alteration of the regimen.


Q: Why is the patient information leaflet important to read?

A: The patient information leaflet contains critical regulatory details essential for safe use. This includes the complete list of official warnings, necessary precautions, all documented side effects, and conditions under which the medicine must not be used (contraindications).


Q: What is the main difference between Tixteller and other similar treatments?

A: Tixteller is officially classified as a non-systemic antibiotic (a rifamycin derivative). This classification is due to its low systemic absorption, meaning its action is primarily limited to the gut lumen, where it targets susceptible bacteria.


Q: Why is Tixteller sometimes used with another medicine?

A: For certain indications, such as the management of Hepatic Encephalopathy, Tixteller is often used as an addition to other treatments. Clinical studies have shown that using Tixteller in combination, typically with lactulose, provides complementary effects in reducing elevated ammonia levels.


Q: Can Tixteller cause weight gain or weight loss?

A: Official adverse reaction lists do include side effects that relate to changes in weight or fluid balance. These documented effects include changes in appetite and the occurrence of fluid retention in the tissues, such as swelling (edema) or fluid accumulation in the abdomen (ascites).


Q: Is it common to feel dizzy or tired when first starting Tixteller?

A: Dizziness and fatigue are listed in the official adverse reactions data and are classified as common side effects for some approved uses. This means they were observed relatively frequently in the clinical studies that led to the drug's approval.


Q: What happens if I take too much Tixteller?

A: The official documentation provides instructions for overdosage. If you take more than the amount outlined in your dosing regimen, even if you do not notice any immediate problems, official regulatory instructions state that emergency medical attention or consultation with a doctor may be necessary.


Q: Does Tixteller contain lactose or gluten?

A: The required official list of inactive ingredients (excipients) for the film-coated tablet generally does not list lactose or gluten as components. However, for individuals with severe sensitivities, it is recommended to review the full list of excipients with a pharmacist to confirm complete composition details.


Q: Can Tixteller affect my ability to drive or operate machinery?

A: The medicine is not normally expected to impair the ability to drive or use machinery. However, since the official labeling documents dizziness as a possible side effect, the regulatory label notes that individuals who experience dizziness should not drive or operate machinery.


Q: Is Tixteller available in a generic version?

A: The active substance in the medicine is called Rifaximin, which is the generic name for the compound. The availability and specific regulatory approval status of generic Rifaximin products can vary significantly depending on local regulations and the country you are in.


Q: How is Tixteller supplied (e.g., tablet, capsule, liquid)?

A: Tixteller is supplied as a film-coated tablet designed for oral administration. The most commonly available strengths, as listed in the regulatory documents, are the 200 mg and 550 mg tablets.


Q: How does Tixteller's mechanism relate to the disease it treats?

A: The medicine works by reducing the population of certain susceptible gut bacteria. This action helps to lower the level of bacterial byproducts, such as ammonia (key in Hepatic Encephalopathy), or helps to reduce the number of bacteria contributing to symptoms like abdominal pain and bloating (key in Irritable Bowel Distress).


Q: Do I need any special tests before starting Tixteller?

A: The regulatory labeling does not require a general pre-treatment test for all patients. However, official safety notes mandate careful monitoring of the International Normalized Ratio (INR) for patients concurrently taking the blood thinner Warfarin.


Q: What should I do if my symptoms do not improve while taking Tixteller?

A: Official warnings state that if symptoms related to diarrhea worsen or persist for more than 24 to 48 hours, regulatory warnings advise that discontinuation of Tixteller and consultation with a healthcare professional regarding alternative treatments may be necessary.


Q: Why do some people need a different dose than others?

A: Official regulatory documents define specific dosage regimens (different doses and frequencies) that are entirely dependent on the condition being treated. The difference in dose is linked to the approved medical application.


Q: What is the maximum recommended dose for Tixteller?

A: Regulatory labeling defines multiple approved regimens based on the indication. The highest daily amount administered in an approved regimen involves the 550 mg tablet taken three times per day for a short course, or twice per day for the chronic maintenance regimen.


Q: Can Tixteller be crushed or split?

A: The manufacturer of the film-coated tablet formulation has not issued official instructions or confirmation that the tablets may be crushed, cut in half, or chewed. Regulatory labeling indicates that the medicine is administered as the whole, intact tablet.


Q: How long does Tixteller stay in the system?

A: Information derived from pharmacokinetic studies indicates that the elimination half-life of Rifaximin is approximately 5.6 to 6 hours in healthy adults. This figure reflects the amount of time required for half of the substance to be eliminated from the body.


Q: Are there any long-term side effects that studies have looked into?

A: Long-term clinical trials for maintenance use (such as for Hepatic Encephalopathy) have documented adverse reactions that persist over time. These include effects such as joint pain, muscle cramps, and peripheral edema (swelling in the hands or feet).


Q: Does Tixteller interfere with birth control pills?

A: Clinical studies specifically examining this interaction have concluded that Rifaximin does not cause a clinically significant interaction. It is not expected to reduce the effectiveness of oral contraceptive medications.


Q: Can I take vitamins or supplements with Tixteller?

A: Official patient information advises that you should tell your healthcare provider about all prescription medicines, as well as any vitamins, minerals, herbal products, and other supplements you are currently taking.


Q: Can I stop taking Tixteller suddenly?

A: Official patient instructions caution against stopping the medicine without first consulting a doctor. The labeling notes the importance of the complete prescribed course, as interrupting treatment may carry a risk that the underlying symptoms could return.


Q: Is it necessary to take Tixteller at the same time every day?

A: Patients are instructed in the product information to try to take the medicine around the same time each day. This practice is recommended to help maintain a steady and consistent level of the active substance in the gut.


Q: Is Tixteller known to cause any sleep disturbances?

A: The official adverse reaction lists for some approved uses do include reports of insomnia (difficulty sleeping). This effect is generally classified as a common side effect observed during the course of clinical trials.


Q: Can taking Tixteller affect my mood or behavior?

A: Yes, the official safety profile documents several effects related to the nervous system and mood. These documented adverse reactions include reports of low mood, anxiety, confusion, and strange dreams.

How should Tixteller be stored and disposed of?

The official regulatory documents state that Tixteller does not require any special storage conditions. The tablets are stable when kept at ambient conditions and must be stored in the original carton and blister until the expiration date.

Mandatory Storage and Disposal

Requirement Category Official Regulatory Statement
Child Protection Keep this medicine out of the sight and reach of children.
Stability Do not use the medicine after the expiry date (EXP) printed on the packaging.
Disposal Do not throw away via wastewater or household waste. Consult a pharmacist for proper disposal according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tixteller found in:

A-Z Index: